Cotargeting BCL-2 and MCL-1 in high-risk B-ALL

Improving survival outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL) remains a clinical challenge. Relapsed disease has a poor prognosis despite the use of tyrosine kinase inhibitors (TKIs) for Philadelphia chromosome positive (Ph(+) ALL) cases and immunotherapeutic approaches, including...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Adv
Päätekijät: Moujalled, Donia M., Hanna, Diane T., Hediyeh-zadeh, Soroor, Pomilio, Giovanna, Brown, Lauren, Litalien, Veronique, Bartolo, Ray, Fleming, Shaun, Chanrion, Maïa, Banquet, Sébastien, Maragno, Ana-Leticia, Kraus-Berthier, Laurence, Schoumacher, Marie, Mullighan, Charles G., Georgiou, Angela, White, Christine A., Lessene, Guillaume, Huang, David C. S., Roberts, Andrew W., Geneste, Olivier, Rasmussen, Lorna, Davis, Melissa J., Ekert, Paul G., Wei, Andrew, Ng, Ashley P., Khaw, Seong L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2020
Aiheet:
Lymphoid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7322969/
https://ncbi.nlm.nih.gov/pubmed/32569380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001416
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia